ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SGP vs IART // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

SpyGlass Pharma Inc. (NASDAQ) VS. Integra LifeSciences Holdings Corporation (NASDAQ) • 15-METRIC TALLY: SGP 3 — IART 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SGP VS. IART) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SGP IART SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 50.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -3.08% -3.11% +0.03 SGP /fcf-yield <GO>
Operating Margin — -30.20% — TIE /operating-margins <GO>
Net Profit Margin — -31.60% — TIE /net-margins <GO>
Revenue Growth (YoY) — 1.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.64 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 IART /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 72.1 43.7 +28.40 SGP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.09B $998.2M $89.2M SGP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SGP REV IART REV SGP GROSS % IART GROSS % SGP FCF IART FCF
FY 2025 $0 $1.64B — 50.9% -$33.5M -$31.1M
FY 2024 $0 $1.61B — 54.8% -$24.0M $25.0M
FY 2023 — $1.54B — — — $140.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SGP // BETA —
IART // BETA —